ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
132.95
+0.01 (+0.00%)
As of 11:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close132.94
Open133.20
Bid132.78 x 800
Ask132.84 x 800
Day's Range131.15 - 133.54
52 Week Range92.56 - 140.77
Volume506,152
Avg. Volume1,743,133
Market Cap29.709B
Beta (3Y Monthly)1.57
PE Ratio (TTM)382.03
EPS (TTM)0.35
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est163.24
Trade prices are not sourced from all markets
  • Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials
    CNBC Videos19 days ago

    Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
    Business Wire5 hours ago

    Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases

    - Collaboration furthers Alexion’s complement leadership with expansion into peptide therapies -

  • Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
    Business Wire5 hours ago

    Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

    Alexion Pharmaceuticals, Inc. (ALXN) and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn).

  • Markityesterday

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALXN are favorable, with net inflows of $10.95 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool9 days ago

    Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript

    DRNA earnings call for the period ending December 31, 2018.

  • If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today
    Simply Wall St.9 days ago

    If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today

    While not a mind-blowing move, it is good to see that the Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) share price has gained 12% in the last three months. But that doesn't changeRead More...

  • Business Wire12 days ago

    Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve

    Additionally, patients who had previously been treated with placebo in REGAIN showed rapid and significant improvement upon starting treatment with SOLIRIS in the open-label extension (OLE). “Symptom persistence is a major challenge in the treatment of gMG,” said Srikanth Muppidi, M.D., Clinical Associate Professor, Department of Neurology and Neurosciences at Stanford University School of Medicine.

  • Why Is Alexion (ALXN) Up 9.7% Since Last Earnings Report?
    Zacks14 days ago

    Why Is Alexion (ALXN) Up 9.7% Since Last Earnings Report?

    Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire14 days ago

    Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Mass. life science leaders say outgoing FDA head was an 'advocate for modernization'
    American City Business Journals14 days ago

    Mass. life science leaders say outgoing FDA head was an 'advocate for modernization'

    Commissioner Scott Gottlieb surprised the life sciences industry Tuesday when he announced his resignation.

  • Business Wire15 days ago

    Alexion to Present at the Cowen 39th Annual Health Care Conference

    Alexion Pharmaceuticals today announced that management will present at the Cowen 39th Annual Health Care Conference in Boston, MA on Tuesday, March 12, 2019 at 11:20 a.m., ET.

  • These 10 New Drugs Expected In 2019 Are On The Blockbuster Track
    Investor's Business Daily20 days ago

    These 10 New Drugs Expected In 2019 Are On The Blockbuster Track

    A series of drugs expected to launch in 2019 could hit blockbuster status in the next five years, according to a report. The potential blockbuster drugs could top $18 billion in 2024 sales.

  • Business Wire20 days ago

    Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day

    Alexion Pharmaceuticals, Inc. (ALXN) is honored to support Rare Disease Day 2019 with the launch of #RallyforRare, a global social media campaign that aims to raise awareness of rare diseases. #RallyforRare will serve as a platform for education and conversation about rare diseases and how they impact the lives of those living with one. Rare Disease Day is an opportunity to be part of a global call to action to better coordinate all aspects of care for people living with rare diseases.

  • America's 'inefficient' health care system is driving our fiscal instability: Powell
    Yahoo Finance22 days ago

    America's 'inefficient' health care system is driving our fiscal instability: Powell

    Health care costs are continuing to grow, and it’s increasingly alarming for policymakers.

  • InvestorPlace23 days ago

    5 Clinical-Stage Biotech Stocks to Buy

    Last year was not kind to many biotech stocks. When investors abandoned high growth equities as the economy and market got rocky, biotech stocks were some of the first to go. This was especially true for many of the clinical-stage drug developers with no actually marketed products under their belts. The equal-weighted SPDR S&P Biotech (NYSEArca:XBI) -- which has a high concentration of smaller biotech stocks -- managed to lose around 24% in 2018.Investors clearly were not willing to gamble on those smaller stocks that don't have revenues.But the new year is shaping to be a bit better for biotech stocks in general and those clinical-stage developers. So far, risk has once again returned to the menu and the effects of the government shutdown on the FDA are no longer an issue. Investors have once again taken a shine to early-stage drug developers. The XBI is up more than 16% year-to-date.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd more gains could be in store for the clinical biotech stocks. * 7 Cheap Stocks That Make the Grade Even better is that, prices for many of the earlier developers remain below their peaks. This gives investors plenty of chances to snag-up some promising drug firms with some serious potential under their belts. But which ones to buy? Here are five clinical stage biotech stocks to buy today. Nightstar Therapeutics (NITE)One of the hottest trends in biotech stocks is gene therapy. There are thousands of diseases and disorders are caused by faulty genes. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight faulty ones, replacing/editing missing/broken genes or actually "turning off" the genes causing problems. It's a major breakthrough and is just starting to get critical mass with the FDA and drug makers.On the ground floor of that is Nightstar Therapeutics (NASDAQ:NITE). NITE's main focus is on gene therapies for patients who suffer from rare inherited retinal diseases that would otherwise progress to blindness. The biotech has several candidates in various trials. It's lead product targeting a condition called choroideremia begun enrolling for phase 3 trials. Choroideremia is a rare disease that has no current treatments. Data so far for NITE's work here has been more than promising and has received several fast-track FDA designations based on early data.But NITE isn't done yet.The clinical stage biotech stock's work on X-Linked Retinitis Pigmentosa -- another genetic eye disease -- has proven successful as well. Nightstar was successful in its "proof of concept" during the fall of last year. Phase 2/3 data is expected in mid-2019.Both of these as well as NITE's full pipeline of other therapies could be very fruitful for investors over the next few years. And that makes the biotech stock a big buy. Ra Pharmaceuticals Inc. (RARX)Clinical biotech stocks can win if they are able to offer something better than established treatments. That's exactly Ra Pharmaceuticals' (NASDAQ:RARX) bag.Generalized Myasthenia Gravis (gMG) is a serious condition that progressively weakens muscles. It's rare and only around 60,000 Americans suffer from the disorder. The only drug approved to treat is the insanely priced Soliris. Soliris and its hefty price tag have allowed Alexion Pharmaceuticals (NASDAQ:ALXN) to reap billions in revenues. But that might end if RARX has its way.At the end of last year, RARX's lead therapy zilucoplan posted amazing phase 2 results for gMG. Digging into the data, Ra's drug was able to improve patients' quantitative MG scores by 6 points. Soliris was approved after improving patients scores by just 4.6 points. Now, that Soliris improvement was at a much great rate than those receiving a placebo, RA wasn't too far behind. What it really means is that RARX should be able to meet with the FDA to discuss the design of a phase 3 trial and work towards getting the drug approved.With a strong balance sheet and continued insider stock purchases, Ra Pharmaceuticals has plenty of potential to pay for that trial and actually see it to the end. * 5 Dow Jones Stocks That Will Lead the Market Higher For investors, with blockbuster replacement looming, RARX stock is alone biotech that shouldn't' be missed. Aurinia Pharmaceuticals (AUPH)Clinical stage biotech stocks tend to be gambles. That's sort of the situation with Aurinia Pharmaceuticals (NASDAQ:AUPH). A ton hinges on a late-stage trial reporting at the end of the year. However, it's a gamble that may be worth looking at.For AUPH, the mission remains to tackle lupus. Lupus remains one of the least understood auto-immune diseases. With lupus, the body's immune system mistakenly attacks healthy tissue. That's pretty bad by itself, however, many people often develop lupus nephritis (LN) and succumb to life-threatening kidney damage. Aurinia is developing a compound called voclosporin works by inhibiting an enzyme that activates immune cells. Voclosporin worked amazingly in phase 2 trials and had a high rate of success for LN patients.Aurinia should wrap phase 3 trials for the drug and LN treatments at the end of 2019. If it hits, analysts now peg sales of the medicine to fetch around $1 billion annually. Naturally, investors have placed a lot of stock on the drug and AUPH's potential. If it hits, investors could be looking at huge blockbuster and a sharp increase in AUPH stock.And if it doesn't, Aurinia may be ok as the firm is developing voclosporin for various indications as well. But given the potential, the firm may be one of the best clinical biotech stocks to buy for a gamble. Arena Pharmaceuticals (ARNA)Partnerships can mean big things for clinical stage biotech stocks. A prime example is Arena Pharmaceuticals (NASDAQ:ARNA).For starters, ARNA has a rich pipeline of treatments in mid-to-late stages of trials. This includes drugs for Ulcerative Colitis, Crohn's Disease, and IBS. That alone is worth the price of admission. But where Arena could be winning is in its drug Ralinepag. Ralinepag has been touted as potentially a best-in-class medicine for treating pulmonary arterial hypertension. So, naturally, any biotech firm that has drugs already on the market that could be threatened by the future blockbuster is willing to bend over backward to defend their position.And that's just United Therapeutics (NASDAQ:UTHR) did by paying Arena $800 million cash up-front as well as up to $400 million in milestone payments and double-digit royalties on sales in order to license Ralinepag.For Arena, this is a win-win. They get cash to develop it and other drugs in their platform and still are able to share in the long-term success of the drug. For investors, this is a big win as well and shows that ARNA's management is thinking about the total portfolio and not just one drug. * 5 Big-Yield REITs to Check Out Now In the end, Arena should have enough money to make its pipeline a reality and get more of its drugs out to market. That makes the clinical biotech stock one to bet on. Galapagos (GLPG)When it comes to late-stage biotech stocks or really any drug manufacturer, pipeline means everything. It's what drives your valuation and future potential. Luckily for clinical-stage firm Galapagos (NASDAQ:GLPG), its pipeline is very robust indeed. GLPG has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. But what separates Galapagos is that that pipeline is actually churning out real results.Partnering with biotech-giant Gilead (NASDAQ:GILD), GLPG's Filgotinib is quickly becoming a winner and after impressive phase-3 data, the duo has moved closer to marketing the drug rheumatoid arthritis. At the same time, Galapagos has scored wins in cystic fibrosis, idiopathic pulmonary fibrosis, systemic sclerosis and a fast-track designation for its osteoarthritis treatment.All in all, GLPG has many shots on goal to make it. That's very important to a clinical-stage biotech stock. And yet, last years rout of the sector sent shares of GLPG downwards and they've stayed that way. Today, Galapagos is still about 17% below its 2018 peak of $117 per share.Given its huge pipeline -- that is increasingly winning in trials -- that difference may not last long. When it comes to clinical stage biotech stocks, GLPG is one you must own.Disclosure: At the time of writing, Aaron Levitt was Long the iShares Nasdaq Biotechnology ETF -- which holds a position in GILD, ALXN, AUPH, GLPG, RARX, UTHR and ARNACompare Brokers The post 5 Clinical-Stage Biotech Stocks to Buy appeared first on InvestorPlace.

  • Business Wire26 days ago

    FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the use of SOLIRIS® (eculizumab), the company’s first C5 complement inhibitor, as a treatment for patients with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) auto antibodies. The FDA granted priority review and set a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2019.

  • Business Wire27 days ago

    Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Alexion Pharmaceuticals today announced that management will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET.

  • TheStreet.com27 days ago

    Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

    Building one of the world's largest hedge funds is bound to bring some notice, so Ray Dalio likely is used to having people follow his stock picks. Now that the 13Fs are public, we can see which stocks Dalio's Bridgewater Associates chose as new investments in the fourth quarter of 2018. Ameriprise, which spun off from American Express back in 2005, had a successful year at a time when the finance and asset management industry was struggling.

  • IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range
    Investor's Business Daily28 days ago

    IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range

    Biotech stocks have been recovering from a steep drop late last year. One of the leading players, Alexion Pharmaceuticals, is flirting with a breakout.

  • Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
    Zackslast month

    Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

    Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT

    Q4 2018 Alexion Pharmaceuticals Inc Earnings Call

  • The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
    Zackslast month

    The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

    The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

  • Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
    Zackslast month

    Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

    Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

  • Business Wirelast month

    Alexion Announces Creation of New Roles on Executive Leadership Team

    Alexion Pharmaceuticals, Inc. (ALXN) today announced the creation of new roles within its executive leadership team. Anne-Marie Law has been appointed to the newly created role of Chief Patient and Employee Experience Officer. Aradhana Sarin, M.D., has been appointed to the newly created role of Chief Strategy and Business Officer.